.png)
SummaryA discontinued drug is a medicinal product that the marketing authorisation holder has permanently stopped placing on the market, which in German is recorded as "Außer Vertrieb". This is legally and commercially distinct from a temporary supply shortage (Lieferengpass), where the product still exists and the authorisation remains valid, and from a lapsed or revoked marketing authorisation, where the legal permission to sell the product no longer exists at all.
Those three states are routinely conflated, including inside pharmaceutical companies. They are not interchangeable. Each has a different cause, a different duration, a different legal basis and a different consequence for the patient in front of you and for the business case on your desk.
This article sets out the distinctions precisely, explains why products get discontinued, what happens clinically when they do, why a discontinuation is one of the more reliable business development signals available in pharmaceutical data, and why the historical record of a withdrawn product is far more valuable than the current-state view most systems provide.
The cleanest way to hold these apart is to ask two questions about any product: does the marketing authorisation still exist, and is the holder still supplying it?
| State | German term | Authorisation status | Duration | Typical trigger | What it means operationally |
|---|---|---|---|---|---|
| Supply shortage | Lieferengpass | Valid and unaffected | Temporary, by definition an interruption expected to exceed roughly two weeks | Manufacturing fault, API sourcing, demand spike, batch failure | Product will return. Bridge the gap with alternatives, imports or rationing |
| Market withdrawal | Außer Vertrieb | Usually still valid, at least initially | Permanent as a commercial decision | Commercial, portfolio pruning, pricing outcome, product replaced by successor | Product will not return. Therapy must be converted, not bridged |
| Authorisation lapsed | Erlöschen der Zulassung | Gone | Permanent and legal | Sunset clause, holder surrenders authorisation, non-renewal | The product may not legally be placed on the market at all |
| Authorisation revoked or suspended | Rücknahme, Widerruf, Ruhen | Withdrawn or paused by the authority | Permanent or until resolved | Safety finding, negative benefit-risk assessment, quality defect | Regulatory action. Often triggers recall and prescriber communication |
Note the sequencing that makes the middle two rows so easy to confuse. A commercial withdrawal usually comes first, and the authorisation lapse follows later, often years later. That gap is where most data quality problems live.
Three provisions of the Arzneimittelgesetz (AMG) do the substantive work here, and it is worth citing the right one.
Notification of discontinuation is governed by § 29 AMG. Under § 29 Abs. 1c AMG, the marketing authorisation holder must notify the competent higher federal authority when placing the medicine on the market is discontinued either temporarily or permanently ("vorübergehend oder endgültig eingestellt"). The notification is due at the latest two months before the discontinuation, unless circumstances outside the holder's control prevent that. This is the legal hook that makes discontinuation a reportable, and therefore trackable, event rather than something a company simply does quietly.
The sunset clause sits in § 31 AMG. Under § 31 Abs. 1 Satz 1 Nr. 1 AMG, an authorisation expires if the authorised medicine is not placed on the market within three years of the authorisation being granted, or if a medicine that was placed on the market subsequently ceases to be on the market for three consecutive years. This mirrors the sunset provision in EU pharmaceutical law. The practical consequence is a delay: a product taken Außer Vertrieb in year one may retain a formally valid authorisation until year four. Anyone reading authorisation status alone as a proxy for availability will be wrong for three years.
Shortage notification is a different regime again. § 52b AMG carries the supply obligations, including in Abs. 3a the duty of pharmaceutical companies to inform hospitals immediately of known supply shortages affecting prescription medicines used in inpatient care. Shortage reporting and discontinuation reporting are separate legal duties with separate destinations. Treating the shortage database as a complete register of unavailability is a common and expensive mistake.
Discontinuation is rarely a single-cause event, but the drivers cluster into four groups.
That last mechanism is the reason shortage history and discontinuation status have to be read together rather than in separate systems. The transition between them is where the signal is.
For a patient stabilised on a medicine, discontinuation is not an inventory event. It is a forced therapeutic change.
Clinically, the consequences fall into a familiar sequence. Prescribers must convert patients to an alternative, which for narrow therapeutic index substances, antiepileptics, immunosuppressants and psychotropics carries real risk. Dose equivalence is often approximate rather than exact. Excipient differences matter for allergy and intolerance patients. Where no equivalent product exists nationally, the fallback options are import under the relevant national provisions or extemporaneous compounding, both of which shift work, cost and liability onto the pharmacy.
Hospital pharmacy carries the heaviest share of this. A discontinued product on a hospital formulary triggers formulary revision, protocol updates, revalidation of automated dispensing and compounding records, staff communication and, frequently, a new tender. Paediatric and rare disease indications are hit hardest, because the commercial rationale for discontinuation is strongest exactly where the patient population is smallest.
The operational reality reported by hospital procurement teams is that unavailability frequently surfaces only at the end of the ordering process, after the requisition has already been raised. When the reason for that unavailability turns out to be permanent rather than temporary, the response required is completely different, and knowing which case you are in on day one rather than week three is the entire value of accurate status data.
This is the part that is systematically underused. When a product leaves a market, something is left behind: a treated population, a set of prescribers, a reimbursement pathway and a competitive position that just vacated.
Read structurally, a discontinuation can indicate any of the following.
None of these reads are possible from a national current-state product list. They require the discontinued product to still be in the dataset, with its history attached, and ideally with its counterparts in other markets alongside it.
A workable monitoring routine draws on more than one register, because no single source covers the whole picture.
| Source | Covers | Known limitation |
|---|---|---|
| BfArM shortage database | Reported supply shortages for human medicines in Germany, current and resolved, with an archive | Excludes vaccines and blood products. Reporting scope is defined, not universal |
| Paul-Ehrlich-Institut | Shortages for human vaccines and other biomedicinal products | Separate portal and separate list from BfArM |
| BfArM AMIce medicinal products information system | Authorisation status of approved and formerly approved medicines, cut-off 30 April 1990, 332,971 records as of January 2025, updated on business days | Administrative authorisation data. It tells you about the authorisation, not about whether the product is on a wholesaler's shelf |
| EMA shortages catalogue and ESMP | Shortages assessed at EU level, plus links to national registers | EU-level assessment scope. National detail stays national |
| Article 57 and national product registers | Authorised products per member state | Fragmented across 27 national authorities in as many formats |
The practical routine that follows from this: watch shortage entries that persist beyond a plausible resolution window, watch § 29 discontinuation notifications, watch authorisation status changes for lapses that confirm an earlier commercial exit, and cross-check every national disappearance against the substance's status in neighbouring markets before concluding the product is gone.
Here is the structural problem with almost every drug database in commercial use. They are built to answer the question "what can I dispense today". When a product goes Außer Vertrieb, it is removed from the current master data, and with it goes the price history, the package configurations, the reimbursement status and the entire record that it ever existed.
That deletion is defensible for a dispensing system. It is disastrous for analysis. The questions that matter to business development, market access, pricing and health economics are all retrospective:
Manufacturers ask for exactly this, and they ask for it directly.
"What mattered to us was the shortage reports, whether there had ever been a report for a particular product in the past." Market access, pharmaceutical manufacturer, translated from German
This is where pharmazie.com is scoped differently from a current-state database. The platform holds price and product history back to market launch, plus archive data covering products that have left the market, alongside more than 25 pharmaceutical databases in a single search covering over 50,000 German and more than 120,000 international products across 50+ countries. DACON has been maintaining this data since 1989, which is why the archive reaches as far back as it does.
The claim is deliberately narrow. For "what can I dispense right now", plenty of tools work. For "what happened to this product, when, at what price, and what is its status in eleven other countries", a current-state database cannot answer the question at all, because the data required was deleted at the moment it became interesting.
To make this operational rather than anecdotal, three things need to be true of your data layer. It must retain products after they leave the market, with the date and reason where available. It must distinguish shortage from withdrawal from authorisation lapse as separate states rather than one undifferentiated "not available" flag. And it must be comparable across countries, so that a German discontinuation can be checked against the same substance elsewhere in Europe before anyone concludes the molecule is gone.
Get those three right and discontinuation stops being an operational irritant reported by an angry ward pharmacist and becomes what it actually is: one of the few genuinely forward-looking signals in pharmaceutical master data, telling you where a market has just opened up, which competitor is retreating from which therapeutic area, and which product might be worth acquiring from a holder that no longer wants it.
This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.
